Don't we all (CYP holders) feel a bit more confident after today's Q&A session?
No not all of us.
I listened afterwards so heard the questions and answers afterwards.
Kilian didn't advise of any further patients being recruited in either absolute number terms or percentage terms - the presentation spoke of the first one announcements since spoke in terms of about 5% - Kilian blinked into the question from the host that seemed like he was pronouncing mesenchymal stem cells like he had a foreign language in his mouth.
We are half way through 2024. I doubt Kilian will recruit by end of year.
Kilian hasn't gone on the record over even the control arm to treatment arm split. He retains wiggle room because shareholders haven't required him to put on record whether it is a term of his arrangements with clinical trial sites that half the patients will go to a control arm or a just a third of them. That goes to recruitment prospects potentially and trial speed and also to potentially the usefulness of the trial results for partnering. A better designed trial is better evidence for partners.
As for his deft handling of the question about orphan drugs - his answer that in cells the process is the product sounded to me like he was commenting from a long way away. IF the process is the product then say OA gets good results and we want a lot of it - more than 2D manufacturing can produce - then we'd have to go back under process is the product thinking and show 3D produced product was not different to 2D produced product so enough could be produced to supply a market for OA worldwide. That would take time.
Kilian is acting like a highly paid tourist wandering around at shareholders expense and your loving him for it.
CYP Price at posting:
29.5¢ Sentiment: Hold Disclosure: Held
(20min delay)